Literature DB >> 17474856

Flavonoids and prostate cancer risk: a study in Italy.

Cristina Bosetti1, Francesca Bravi, Renato Talamini, Maria Parpinel, Patrizia Gnagnarella, Eva Negri, Maurizio Montella, Pagona Lagiou, Silvia Franceschi, Carlo La Vecchia.   

Abstract

Flavonoids have been associated with a reduced risk of lung, digestive tract, and certain hormone-related cancers. With reference to prostate cancer, a few epidemiological studies have found an inverse relation with intake of isoflavones, flavonols, and flavones, although the evidence remains limited and inconsistent. The role of six principal classes of flavonoids on prostate cancer was investigated using data from a multicentric case-control study conducted between 1991 and 2002 in Italy. This included 1,294 incident, histologically confirmed carcinomas of the prostate and 1,451 controls admitted to the same hospitals as cases for a wide spectrum of acute, non-neoplastic conditions. The patients' usual diet was assessed using a validated and reproducible food-frequency questionnaire; food and beverage content of six major classes of flavonoids was obtained from the U.S. Department of Agriculture. No association between prostate cancer risk was found with any of the flavonoids analyzed: the multivariate odds ratios for the highest versus the lowest quintile of intake were 0.96 (95% confidence interval, CI = 0.75-1.23) for flavanones, 1.3 (95% CI = 1.01-1.69) for flavan-3-ols, 1.23 (95% CI = 0.95-1.61) for flavonols, 1.09 (95% CI = 0.85-1.40) for flavonols, 1.18 (95% CI = 0.91-1.53) for anthocyanidins, 0.98 (95% CI = 0.76-1.26) for isoflavones, and 1.20 (95% CI = 0.92-1.58) for total flavonoids, all nonstatistically significant. Thus, the results of the present study do not support a protective effect of flavonoids on prostate cancer in this Italian population, characterized by a high intake of flavonoid-containing foods (except isoflavone-rich foods).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17474856     DOI: 10.1207/s15327914nc5602_1

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  20 in total

1.  A new class of flavonol-based anti-prostate cancer agents: Design, synthesis, and evaluation in cell models.

Authors:  Xiang Li; Guanglin Chen; Xiaojie Zhang; Qiang Zhang; Shilong Zheng; Guangdi Wang; Qiao-Hong Chen
Journal:  Bioorg Med Chem Lett       Date:  2016-07-22       Impact factor: 2.823

Review 2.  Dietary antioxidants and prostate cancer: a review.

Authors:  Terrence M Vance; Joseph Su; Elizabeth T H Fontham; Sung I Koo; Ock K Chun
Journal:  Nutr Cancer       Date:  2013       Impact factor: 2.900

3.  Nitrogen-containing derivatives of O-tetramethylquercetin: Synthesis and biological profiles in prostate cancer cell models.

Authors:  Pravien Rajaram; Ziran Jiang; Guanglin Chen; Alyssa Rivera; Alison Phasakda; Qiang Zhang; Shilong Zheng; Guangdi Wang; Qiao-Hong Chen
Journal:  Bioorg Chem       Date:  2019-03-19       Impact factor: 5.275

4.  Kaempferol inhibits angiogenesis and VEGF expression through both HIF dependent and independent pathways in human ovarian cancer cells.

Authors:  Haitao Luo; Gary O Rankin; Lingzhi Liu; Matthew K Daddysman; Bing-Hua Jiang; Yi Charlie Chen
Journal:  Nutr Cancer       Date:  2009       Impact factor: 2.900

5.  Kaempferol enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc.

Authors:  Haitao Luo; Matthew K Daddysman; Gary O Rankin; Bing-Hua Jiang; Yi C Chen
Journal:  Cancer Cell Int       Date:  2010-05-11       Impact factor: 5.722

Review 6.  Anthocyanins and their role in cancer prevention.

Authors:  Li-Shu Wang; Gary D Stoner
Journal:  Cancer Lett       Date:  2008-06-20       Impact factor: 8.679

7.  Relationship of serum levels and dietary intake of isoflavone, and the novel bacterium Slackia sp. strain NATTS with the risk of prostate cancer: a case-control study among Japanese men.

Authors:  Yoshie Nagata; Yukiko Sugiyama; Fumimasa Fukuta; Akio Takayanagi; Naoya Masumori; Taiji Tsukamoto; Hiroshi Akasaka; Hirofumi Ohnishi; Shigeyuki Saitoh; Tetsuji Miura; Kaoru Moriyama; Hirokazu Tsuji; Hideyuki Akaza; Mitsuru Mori
Journal:  Int Urol Nephrol       Date:  2016-06-04       Impact factor: 2.370

8.  Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway.

Authors:  Sanjeev Shukla; Natarajan Bhaskaran; Melissa A Babcook; Pingfu Fu; Gregory T Maclennan; Sanjay Gupta
Journal:  Carcinogenesis       Date:  2013-09-25       Impact factor: 4.944

9.  Structure-activity relationship and pharmacokinetic studies of 3-O-substitutedflavonols as anti-prostate cancer agents.

Authors:  Xiang Li; Changde Zhang; Shanchun Guo; Pravien Rajaram; Maizie Lee; Guanglin Chen; Ryan Fong; Aaron Gonzalez; Qiang Zhang; Shilong Zheng; Guangdi Wang; Qiao-Hong Chen
Journal:  Eur J Med Chem       Date:  2018-08-22       Impact factor: 6.514

10.  Dietary Total Antioxidant Capacity is Inversely Associated with Prostate Cancer Aggressiveness in a Population-Based Study.

Authors:  Terrence M Vance; Ying Wang; L Joseph Su; Elizabeth T H Fontham; Susan E Steck; Lenore Arab; Jeannette T Bensen; James L Mohler; Ming-Hui Chen; Ock K Chun
Journal:  Nutr Cancer       Date:  2016-02-04       Impact factor: 2.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.